These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 28509146)

  • 1. Efficacy of tocilizumab, a humanized neutralizing antibody against interleukin-6 receptor, in progressive renal injury associated with Castleman's disease.
    Maeshima A; Nakasatomi M; Henmi D; Yamashita S; Kaneko Y; Kuroiwa T; Hiromura K; Nojima Y
    CEN Case Rep; 2012 May; 1(1):7-11. PubMed ID: 28509146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Membranous nephropathy associated with multicentric Castleman's disease that was successfully treated with tocilizumab: a case report and review of the literature.
    Saiki R; Katayama K; Hirabayashi Y; Oda K; Fujimoto M; Murata T; Nakajima A; Dohi K
    BMC Nephrol; 2021 Jun; 22(1):216. PubMed ID: 34107915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment of a mesangial proliferative glomerulonephritis with interstitial nephritis associated with Castleman's disease by an anti-interleukin-6 receptor antibody (tocilizumab).
    Otani N; Morishita Y; Oh I; Saito O; Takemoto F; Muto S; Kusano E
    Intern Med; 2012; 51(11):1375-8. PubMed ID: 22687845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicentric Castleman's disease with renal amyloidosis and mesangial proliferative glomerulonephritis: a case report.
    Tan Z; Wang L; Wang C; Gao L; Yang Y
    Int J Clin Exp Med; 2015; 8(2):2966-73. PubMed ID: 25932265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-6 receptor inhibition with tocilizumab in various renal involvements associated with multicentric Castleman's disease: a report of three cases.
    Komaba H; Nakazawa T; Yamaguchi Y; Kumagai S; Fukagawa M
    NDT Plus; 2008 Dec; 1(6):423-426. PubMed ID: 28656995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case of multicentric Castleman's disease with membranoproliferative glomerulonephritis type 3-like lesion.
    Nagai K; Usui J; Noguchi K; Unai K; Hiwatashi A; Arakawa Y; Togashi A; Morito N; Saito C; Yoh K; Tsuruoka S; Kojima H; Aita K; Nagata M; Yamagata K
    Pathol Int; 2011 Nov; 61(11):686-90. PubMed ID: 22029682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Membranoproliferative glomerulonephritis-like lesion with fibrillary deposition associated with multicentric Castleman's disease].
    Akimoto H; Shirai M; Usutani S; Masaoka H; Hidaka S; Kakuta S; Kawasugi K; Nagase M
    Nihon Jinzo Gakkai Shi; 1998 May; 40(4):301-8. PubMed ID: 9654915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case of Castleman's disease complicated with nephrotic syndrome due to glomerulopathy mimicking membranoproliferative glomerulonephritis.
    Sugimoto T; Ito J; Takeda N; Gasyu I; Okazaki T; Sakaguchi M; Osawa N; Tanaka Y; Oka K; Uzu T; Kashiwagi A
    Am J Med Sci; 2008 Jun; 335(6):495-8. PubMed ID: 18552583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Castleman's disease and mesangial proliferative glomerulonephritis: the role of interleukin-6.
    Lui SL; Chan KW; Li FK; Cheng IK; Chan TM
    Nephron; 1998; 78(3):323-7. PubMed ID: 9546694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Three cases of Castleman's disease mimicking the features of collagen disease].
    Hosaka S; Kondo H
    Ryumachi; 1994 Feb; 34(1):42-7. PubMed ID: 8146727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resolution of membranoproliferative glomerulonephritis complicating angiofollicular lymph node hyperplasia (Castleman's disease).
    Chan TM; Cheng IK; Wong KL; Chan KW
    Nephron; 1993; 65(4):628-32. PubMed ID: 8302422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicentric Castleman's disease associated with glomerular microangiopathy and MPGN-like lesion: does vascular endothelial cell-derived growth factor play causative or protective roles in renal injury?
    Seida A; Wada J; Morita Y; Baba M; Eguchi J; Nishimoto N; Okino T; Ichimura K; Yoshino T; Makino H
    Am J Kidney Dis; 2004 Jan; 43(1):E3-9. PubMed ID: 14712466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Case of Castleman's Disease with a Marked Infiltration of IgG4-Positive Cells in the Renal Interstitium.
    Sawada E; Shioda Y; Ogawa K; Iwashita T; Ono Y; Hasegawa H; Maeshima A
    Diagnostics (Basel); 2024 Feb; 14(5):. PubMed ID: 38472948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Case of Castleman's Disease during the Long-Term Course of Membranous Nephropathy.
    Nakajima S; Nagai K; Sakata A; Usui J; Yamagata K; Ueda A
    Case Rep Nephrol; 2023; 2023():4926000. PubMed ID: 36873956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Membranoproliferative glomerulonephritis in the setting of multicentric angiofollicular lymph node hyperplasia (Castleman's disease) complicated by Evan's syndrome.
    Gakiopoulou H; Korkolopoulou P; Paraskevakou H; Marinaki S; Voulgarelis M; Stofas A; Lelouda M; Lazaris AC; Boletis J; Patsouris E
    J Clin Pathol; 2010 Jun; 63(6):552-4. PubMed ID: 20439324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease.
    Matsuyama M; Suzuki T; Tsuboi H; Ito S; Mamura M; Goto D; Matsumoto I; Tsutsumi A; Sumida T
    Intern Med; 2007; 46(11):771-4. PubMed ID: 17541233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Remission of nephrotic syndrome after thalidomide therapy in a patient with Castleman's disease.
    Menegato MA; Canelles MF; Tonutti E; Pizzolitto S
    Clin Nephrol; 2004 May; 61(5):352-6. PubMed ID: 15182131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of tocilizumab in a patient with pulmonary arterial hypertension associated with Castleman's disease.
    Arita Y; Sakata Y; Sudo T; Maeda T; Matsuoka K; Tamai K; Higuchi K; Shioyama W; Nakaoka Y; Kanakura Y; Yamauchi-Takihara K
    Heart Vessels; 2010 Sep; 25(5):444-7. PubMed ID: 20676969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Siltuximab: a new option for the management of Castleman's disease.
    Barquero N
    Drugs Today (Barc); 2015 Jan; 51(1):21-8. PubMed ID: 25685858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased interleukin-6 (IL-6) production in a young child with clinical and pathologic features of multicentric Castleman's disease.
    Kinney MC; Hummell DS; Villiger PM; Hourigan A; Rollins-Smith L; Glick AD; Lawton AR
    J Clin Immunol; 1994 Nov; 14(6):382-90. PubMed ID: 7883866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.